West Family Investments Inc. Reduces Stake in Novo Nordisk A/S (NYSE:NVO)

West Family Investments Inc. trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,330 shares of the company’s stock after selling 388 shares during the quarter. Novo Nordisk A/S makes up 0.9% of West Family Investments Inc.’s holdings, making the stock its 28th biggest position. West Family Investments Inc.’s holdings in Novo Nordisk A/S were worth $2,517,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Westside Investment Management Inc. increased its holdings in shares of Novo Nordisk A/S by 83.3% in the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after buying an additional 649 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $2,408,000. Lazard Asset Management LLC lifted its position in shares of Novo Nordisk A/S by 182.2% in the 3rd quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after purchasing an additional 964,640 shares during the period. CENTRAL TRUST Co lifted its position in shares of Novo Nordisk A/S by 111.6% in the 3rd quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after purchasing an additional 3,166 shares during the period. Finally, Ieq Capital LLC increased its stake in shares of Novo Nordisk A/S by 136.6% in the 3rd quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock worth $2,498,000 after acquiring an additional 15,860 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NVO has been the subject of several research reports. BMO Capital Markets initiated coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $4.04 during trading hours on Thursday, reaching $125.17. The company had a trading volume of 5,130,547 shares, compared to its average volume of 4,808,741. The business has a fifty day moving average price of $127.22 and a 200-day moving average price of $112.70. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The firm has a market cap of $561.70 billion, a PE ratio of 46.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.43. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.